MTVA: Multiple Upcoming Presentations to Highlight DA-1726 and Vanoglipel
On May 14, 2026, MetaVia, Inc. (MTVA) announced financial results for the first quarter of 2026 and provided a business update. In April 2026, the...
117 Views
MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026
On March 26, 2026, MetaVia, Inc. (MTVA) announced financial results for the fourth quarter and full year 2025 and provided a business update. The...
129 Views
MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726
On January 5, 2026, MetaVia, Inc. (MTVA) announced positive and statistically significant results from the 8-week, non-titrated 48 mg cohort from...
159 Views
MTVA: New Data for Vanoglipel (DA-1241) Presented at AASLD
In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the...
407 Views
MTVA: New Date for Vanoglipel (DA-1241) Presented at AASLD
In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the...
318 Views